Cargando…
Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa
BACKGROUND: Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibiotic under FDA review for the treatment of ABSSSI. Previous studies determined DLX bacterial stasis and 1-log(10) bacterial reduction free AUC(0-24) / MIC (fAUC(0-24)/MIC) targets for Escherichia coli (EC) and Pseudomonas aerug...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631342/ http://dx.doi.org/10.1093/ofid/ofx163.1228 |